NT219
CAS No. 1198078-60-2
NT219( —— )
Catalog No. M35618 CAS No. 1198078-60-2
NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3, enhances the aggregation of misfolded prion protein NT219 affects the levels of certain molecular chaperones and inhibits STAT3 phosphorylation NT219 is useful for the study of cancer and neurodegenerative diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 312 | In Stock |
|
| 10MG | 463 | In Stock |
|
| 25MG | 756 | In Stock |
|
| 50MG | 1014 | In Stock |
|
| 100MG | 1376 | In Stock |
|
| 200MG | 1841 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNT219
-
NoteResearch use only, not for human use.
-
Brief DescriptionNT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3, enhances the aggregation of misfolded prion protein NT219 affects the levels of certain molecular chaperones and inhibits STAT3 phosphorylation NT219 is useful for the study of cancer and neurodegenerative diseases.
-
DescriptionNT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1198078-60-2
-
Formula Weight412.26
-
Molecular FormulaC16H14BrNO5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (242.57 mM)
-
SMILESOc1ccc(\C=C\C(=S)NCc2cc(O)c(O)c(O)c2)c(Br)c1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Alberto Bessudo, et al. A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.
molnova catalog
related products
-
Suptavumab
Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.
-
NSC 368262
NSC 368262 is a selective STAT3 inhibitor that alkylates Cys468 in Stat3.
-
Methyl L-histidinate...
Inhibition of histidine decarboxylase in Sprague-Dawley rat stomach assessed as decrease in 14CO2 production with activty value of 1.8 μM
Cart
sales@molnova.com